- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05915975
Integrated Behavioral Healthcare for Youth With Type 1 Diabetes
November 16, 2023 updated by: Luiza Vianna Mali, University of Miami
Integrated Behavioral Healthcare for Low-Income Ethnic Minority Youth With Type 1 Diabetes
The purpose of this study is to understand how behavioral health care that is coordinated with diabetes medical care compared with behavioral care that is provided in the community (and therefore not coordinated with diabetes medical care).
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Luiza V Mali, Ph.D.
- Phone Number: (305)243-6882
- Email: lvm852@miami.edu
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- UNIVERISTY OF MIAMI
-
Contact:
- Luiza V Mali, Ph.D.
- Phone Number: 305-243-6882
- Email: lvm852@miami.edu
-
Principal Investigator:
- Luiza V Mali, Ph.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Type 1 Diabetes diagnosed for one year or more
- Latino or Black ethnicity/race
- Speak and read English or Spanish
- Eligibility for Medicaid
Exclusion Criteria:
- Significant developmental disability
- Serious psychiatric disorder
- Another serious chronic illness
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Behavioral Care Coordinated with Medical Care
Participants in this group will work with a study team member for four months to improve your skills to manage diabetes, to strengthen the child-caregiver relationship, and/or to address emotional challenges that your child might be experiencing.
|
Participants will be meeting with a behavioral health provider during their clinic visit.
Subsequent visits can be held either via telehealth or in-person.
Participants should expect weekly visits during the first two months and less frequent visits (biweekly or monthly) for the last two months.
Some sessions that are provided via telehealth might be video recorded and later reviewed to ensure that the program is being delivered as intended.
|
Active Comparator: Behavioral Care Not Coordinated with Medical Care
Participants will receive the standard of care treatment for four months plus a list of clinics that accept their insurance.
|
Participants will meet with a study team member during their in-person visit and will receive a list of clinics that are panelled with their insurance.
The participants will be responsible for calling the clinics to set up their appointments.
Services might be provided in person or via telehealth based on the participant's preference and the clinics' availability.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Glycemic Control
Time Frame: Baseline and 4 months
|
Will be measured by glycosylated hemoglobin A1c
|
Baseline and 4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Diabetes Self-Management
Time Frame: Baseline and 4 months
|
We will measure Type 1 Diabetes Self-management using the Diabetes Management Questionnaire (DMQ; Score Range: 0-100, higher scores indicate greater adherence to diabetes management).
|
Baseline and 4 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Luiza V Mali, Ph.D., University of Miami
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 7, 2023
Primary Completion (Estimated)
May 30, 2024
Study Completion (Estimated)
May 30, 2024
Study Registration Dates
First Submitted
June 14, 2023
First Submitted That Met QC Criteria
June 14, 2023
First Posted (Actual)
June 23, 2023
Study Record Updates
Last Update Posted (Estimated)
November 20, 2023
Last Update Submitted That Met QC Criteria
November 16, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20230308
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on Behavioral Care Coordinated with Medical Care Intervention
-
John Jay College of Criminal Justice, City University...Indiana University School of MedicineRecruitingYouth | First Episode PsychosisUnited States
-
MDRCKaiser Permanente; Robert Wood Johnson Foundation; Center for Health Care Strategies and other collaboratorsCompletedChronic Conditions Faced by Medicaid Recipients With DisabilitiesUnited States
-
University Hospital, AngersRecruiting
-
Indiana UniversityNational Institute of Mental Health (NIMH); Yale University; University of Michigan and other collaboratorsRecruitingSchizophrenia | Schizoaffective Disorder | Major Depression With Psychotic Features | Schizophreniform Disorders | Bipolar Disorder With Psychotic FeaturesUnited States
-
Kanecia Obie ZimmermanEnrolling by invitationLong COVID | Long Covid19 | Long Covid-19United States
-
St. Joseph's Healthcare HamiltonCanadian Institutes of Health Research (CIHR)RecruitingImproving Medication Prescribing-Related Outcomes for Vulnerable Elderly In Transitions (IMPROVE-IT)Drug-Related Side Effects and Adverse Reactions | Aged | Health Care Costs | Patient DischargeCanada
-
Kanecia Obie ZimmermanEnrolling by invitationLong COVID | Long Covid19 | Long Covid-19United States
-
VA Connecticut Healthcare SystemDonaghue Medical Research FoundationCompletedDiabetic Neuropathy
-
Northwell HealthNational Institute of Mental Health (NIMH)RecruitingFirst Episode PsychosisUnited States
-
Massachusetts General HospitalUniversity of Massachusetts, BostonCompletedPsychological Stress